摘要
目的探讨益气复脉注射液联合重组人脑利钠肽治疗急性心力衰竭(AHF)的临床效果。方法回顾性分析2022年1月—2023年2月桓台县人民医院收治的80例AHF患者的临床资料,根据治疗方法不同分为对照组和观察组,每组40例。两组均接受常规治疗,对照组加用重组人脑利钠肽,观察组予以益气复脉注射液与重组人脑利钠肽治疗。比较两组临床疗效、血清氨基末端脑钠肽前体(NT-proBNP)水平、心功能、运动耐量及不良反应。结果观察组治疗总有效率高于对照组(P<0.05)。治疗后,观察组NT-proBNP水平低于对照组(P<0.05);心功能指标左心室舒张末期内径(LVEDD)低于对照组,左心室射血分数(LVEF)、心脏指数(CI)、每搏输出量(SV)均高于对照组(P<0.05);观察组6 min步行距离(6MWD)高于对照组(P<0.05)。观察组不良反应发生率与对照组比较,差异无统计学意义(P>0.05)。结论应用益气复脉注射液与重组人脑利钠肽联合治疗AHF,能够有效改善患者心功能、运动耐力,降低NT-proBNP水平,且安全性高。
Objective To investigate the effects of Yiqi Fumai Injection combined with recombinant human brain natriuretic peptide in the treatment of acute heart failure(AHF).Methods The clinical data of 80 patients with AHF treated in Huantai People's Hospital from January 2022 to February 2023 were retrospectively analyzed,Participants were divided into control and observation groups(40 patients each)based on treatment regimens,with the control group receiving additional recombinant human brain natriuretic peptide and the observation group received treatment with Yiqi Fupu Injection in addition to the standard care provided to the control group.The clinical efficacy,serum N-terminal pro B type natriuretic peptide(NT-proBNP)level,cardiac function,exercise tolerance and adverse reactions were compared between the two groups.Results The observation group demonstrated superior overall efficacy(P<0.05).After treatment,NT-proBNP levels in the observation group were lower than those in the control group(P<0.05).The left ventricular end-diastolic diameter(LVEDD)was smaller in the observation group,while the left ventricular ejection fraction(LVEF),cardiac index(CI),and stroke volume(SV)were all significantly higher(P<0.05).The 6-minute walk distance(6MWD)in the observation group was significantly higher than that in the control group(P<0.05).Both groups exhibited comparable adverse event rates(P>0.05).Conclusions The combination of Yiqi Fumai Injection and recombinant human brain natriuretic peptide in the treatment of AHF can effectively improve the cardiac function,exercise endurance,and reduce the level of NT-proBNP,with high safety.
作者
葛洁
孙嫣然
GE Jie;SUN Yanran(Department of Cardiology,Huantai People's Hospital,Zibo,Shandong 256400,China)
出处
《医药前沿》
2025年第9期89-92,共4页
Journal of Frontiers of Medicine
关键词
心力衰竭
急性心力衰竭
益气复脉注射液
重组人脑利钠肽
血清氨基末端脑钠肽前体
运动耐量
心功能
治疗效果
Heart failure
Acute heart failure
Yiqi Fumai Injection
Recombinant human brain natriuretic peptide
Serum amino terminal brain natriuretic peptide precursor
Exercise tolerance
Heart function
Therapeutic effect
